bluebird prices β thalassemia gene therapy, first to put majority of revenues at risk

bluebird bio could be the first company to test an outcomes-based pricing model for a gene therapy where the vast majority of the price is at risk.

On Friday, bluebird bio Inc. (NASDAQ:BLUE) announced the price of its β thalassemia gene therapy Zynteglo at €315,000 ($356,500) per year in Europe, amounting to a €1.6 million ($1.8 million) lifetime cost per patient.

The company will try to negotiate contracts based on a five-year, performance-based annuity model

Read the full 740 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE